Philip Macklin

Jul 10, 2024 | bjui-journals.onlinelibrary.wiley.com | Thineskrishna Anbarasan |Mutie Raslan |Philip Macklin |Kanchan Ghosh

1 INTRODUCTION Atypical small acinar proliferation (ASAP), found in 5% of prostate biopsies, represents a focus of atypical cells that fall short of a cancer diagnosis.1 ASAP may be associated with a diagnosis of prostate cancer (PCa) upon repeat biopsy in 25%–50% of patients within 5 years.1 The proportion of these cases that may be classified as being intermediate- or high-grade PCa varies in the literature, ranging from 6.0% to 22.5%.2, 3 Until recently, diagnosis of ASAP was an indication...

Apr 24, 2024 | nature.com | Mike B. Barnkob |Yale Michaels |Philip Macklin |Uzi Gileadi |Salvatore Valvo |Margarida Rei | +14 more

Correction to: Nature Communications https://doi.org/10.1038/s41467-024-47424-z, published online 12 April 2024In this article the title was incorrectly written as ‘Semmaphorin 3A causes immune suppression by inducing cytoskeletal paralysis in tumour-specific CD8+ T cells’ but should have been ‘Semaphorin 3A causes immune suppression by inducing cytoskeletal paralysis in tumour-specific CD8+ T cells’. The original article has been corrected.

Apr 12, 2024 | nature.com | Yale Michaels |Philip Macklin |Uzi Gileadi |Salvatore Valvo |Margarida Rei |Corinna A. Kulicke | +14 more

AbstractSemaphorin-3A (SEMA3A) functions as a chemorepulsive signal during development and can affect T cells by altering their filamentous actin (F-actin) cytoskeleton. The exact extent of these effects on tumour-specific T cells are not completely understood. Here we demonstrate that Neuropilin-1 (NRP1) and Plexin-A1 and Plexin-A4 are upregulated on stimulated CD8+ T cells, allowing tumour-derived SEMA3A to inhibit T cell migration and assembly of the immunological synapse.